Welcome to the CORA 2023
Interactive Program
The congress will officially run on Central European Time (CET/GMT+1)
To check the congress times in your local time Click here
Session Description:
For this symposium, world-renowned experts will focus on key considerations and data that support the importance to treat the underlying disease in patients with active systemic lupus erythematosus (SLE). Experts will highlight key treatment challenges and how targeted treatment approaches can improve long-term patient outcomes. Efficacy and safety data, including real-world evidence will be reviewed to support early intervention with Benlysta ▼ (belimumab). This will help physicians to be aligned on short-term and long-term treatment goals to control active disease and/or flares, while at the same time, reducing the risk of organ damage accrual. This will suggest how a targeted therapy can support disease modification to minimise organ damage and improve patient outcomes in SLE. An industry symposium sponsored and organised by GSK. GSK products will be discussed at this meeting.
Benlysta GB PI is available here.
Benlysta Northern Ireland is available here.